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We have previously described the safety and efficacy of pegylated interferon-α2a
therapy in a cohort of 62 patients with myeloproliferative neoplasm-associated
myelofibrosis followed in centers affiliated to the French Intergroup of
Myeloproliferative neoplasms. In this study, we report their long-term outcomes and
correlations with mutational patterns of driver and non-driver mutations analyzed by
targeted next generation sequencing. The median age at diagnosis was 66 years old,
the median follow-up since starting pegylated interferon was 58 months. At the time
of analysis, 30 (48.4%) patients were alive including 16 still being treated with
pegylated interferon. The median survival of patients with intermediate and high-risk
prognostic Lille and dynamic International Prognostic Scoring System scores treated
with pegylated interferon was increased in comparison to that of historical cohorts.
In addition, overall survival was significantly correlated with the duration of
pegylated interferon therapy (70 30 months after 2 years of treatment, <10). allele
burden was decreased by more than 50% in 58.8% of patients and two patients even
achieved complete molecular response. Next-generation sequencing analyses
performed in 49 patients showed that 28 (57.1%) of them carried non-driver
mutations. The presence of at least one additional mutation was associated with a
reduction of both overall and leukemia-free survival. These findings in a large series
of patients with myelofibrosis suggest that pegylated interferon therapy may provide
a survival benefit for patients with intermediate- or high-risk Lille and dynamic
International Prognostic Scoring System scores. It also reduced the allele burden in
most patients. These results further support the use of pegylated interferon in
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